Hydrochloric Acid → N1-{4-[6-(2-morpholin-4-yl-ethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-pyrimidin-2-yl}-1-phenyl-ethane-1,2-diamine
反応式
C(OC(=O)[NH:7][CH2:8][CH:9]([NH:16][C:17]1[N:22]=[C:21]([C:23]2[C:31]3[C:26](=[N:27][C:28]([NH:32][CH2:33][CH2:34][N:35]4[CH2:40][CH2:39][O:38][CH2:37][CH2:36]4)=[N:29][CH:30]=3)[NH:25][N:24]=2)[CH:20]=[CH:19][N:18]=1)[C:10]1[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1)(C)(C)C.Cl>CCO>[N:35]1([CH2:34][CH2:33][NH:32][C:28]2[N:27]=[C:26]3[NH:25][N:24]=[C:23]([C:21]4[CH:20]=[CH:19][N:18]=[C:17]([NH:16][CH:9]([C:10]5[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=5)[CH2:8][NH2:7])[N:22]=4)[C:31]3=[CH:30][N:29]=2)[CH2:40][CH2:39][O:38][CH2:37][CH2:36]1参加物
4
実験手順
(2-{4-[6-(2-Morpholin-4-yl-ethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-pyrimidin-2-ylamino}-2-phenyl-ethyl)-carbamic acid tert-butyl ester (130 mg, 0.23 mmol) was dissolved in EtOH (4 mL), then HCl (4 mL) was added. The reaction mixture was stirred at room temperature for 15 hours. The solvent was removed under reduced pressure to afford the crude product which was purified by prep-HPLC to afford N1-{4-[6-(2-morpholin-4-yl-ethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-pyrimidin-2-yl}-1-phenyl-ethane-1,2-diamine; hydrochloride. (Yield 25 mg, 19.1%).
後処理
- customThe solvent was removed under reduced pressure
- customto afford the crude product which
- customwas purified by prep-HPLC
出典と根拠
- ORDレコード
- ord-0d1a2d14bacb4bfcb48ed42c84f18be3
- 出典データセット
- uspto-grants-2013_01
- 特許番号
- US08362023B2
反応ノート
読み込み中…